1
|
Wang X, Bao Q, Wang R, Wan B, Wang Y, Qin B, Burgess DJ. Reverse Engineering of Perseris and Development of Compositionally Equivalent Formulations. Int J Pharm 2023; 639:122948. [PMID: 37044228 DOI: 10.1016/j.ijpharm.2023.122948] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2023] [Revised: 03/22/2023] [Accepted: 04/08/2023] [Indexed: 04/14/2023]
Abstract
Six injectable, long-acting in situ forming implant drug products based on poly(lactide-co-glycolide) (PLGA) and N-Methyl-2-Pyrrolidone (NMP) are available on the market. However, generic products, which would likely be more affordable for patients, are not yet available. This is partially due to the unique complexity of these formulations as well as the inherent heterogeneity of PLGA and the challenges in the manufacture and characterization of this polymer. This article focuses on a comprehensive characterization of Perseris (risperidone) in situ forming implant drug product, and the development of compositionally equivalent formulations. The molecular weight (MW), lactide/glycolide (L/G) ratio, end group, blockiness and glass transition temperature (Tg) of PLGA, as well as the crystal form and particle size of risperidone powder used in Perseris were identified through reverse engineering. The dissolved/suspended drug ratio in the final implant suspension for administration, as well as the real-time drug solid state in the solidified Perseris drug depot were investigated. Two compositionally equivalent formulations prepared using customized PLGA polymers with similar properties to the Perseris PLGA showed similar in vitro release and swelling behavior to Perseris as demonstrated using a novel adapter-based dissolution method. The novelty of this dissolution method lies in its ability to control implant shape, generate reproducible data, distinguish different release phases, as well as identify formulation changes. The knowledge gained in this work and the methodology established for characterization of the implant formulations are important for implant formulation development.
Collapse
Affiliation(s)
- Xiaoyi Wang
- Department of Pharmaceutical Sciences, University of Connecticut, Storrs, CT 06269, USA
| | - Quanying Bao
- Department of Pharmaceutical Sciences, University of Connecticut, Storrs, CT 06269, USA
| | - Ruifeng Wang
- Department of Pharmaceutical Sciences, University of Connecticut, Storrs, CT 06269, USA
| | - Bo Wan
- Department of Pharmaceutical Sciences, University of Connecticut, Storrs, CT 06269, USA
| | - Yan Wang
- U.S. Food and drug administration, Silver Springs, MD 20993, USA
| | - Bin Qin
- U.S. Food and drug administration, Silver Springs, MD 20993, USA
| | - Diane J Burgess
- Department of Pharmaceutical Sciences, University of Connecticut, Storrs, CT 06269, USA.
| |
Collapse
|
2
|
Kumar R, Thakur AK, Banerjee N, Chaudhari P. A critical review on the particle generation and other applications of rapid expansion of supercritical solution. Int J Pharm 2021; 608:121089. [PMID: 34530097 DOI: 10.1016/j.ijpharm.2021.121089] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2021] [Revised: 08/29/2021] [Accepted: 09/09/2021] [Indexed: 11/18/2022]
Abstract
The novel particle generation processes of Active Pharmaceutical Ingredient (API)/drug have been extensively explored in recent decades due to their wide-range applications in the pharmaceutical industry. The Rapid Expansion of Supercritical Solutions (RESS) is one of the promising techniques to obtain the fine particles (micro to nano-size) of APIs with narrow particle size distribution (PSD). In RESS, supercritical carbon dioxide (SC CO2) and API are used as solvent and solute respectively. In this literature survey, the application of RESS in the formation of fine particles is critically reviewed. Solubility of API in SC CO2 and supersaturation are the key factors in tuning the particle size. The different approaches to model and predict the solubility of API in SC CO2 are discussed. Then, the effect of process parameters on mean particle size and the particle size distribution are interpreted in the context of solubility and supersaturation. Furthermore, the less-explored applications of RESS in preparation of solid-lipid nanoparticles, liposome, polymorphic conversion, cocrystallization and inclusion complexation are compared with traditional processes. The solubility enhancement of API in SC CO2 using co-solvent and its applications in particle generation are explored in published literature. The development and modifications in the conventional RESS process to overcome the limitations of RESS are presented. Finally, the perspective on RESS with special attention to its commercial operation is highlighted.
Collapse
Affiliation(s)
- Rahul Kumar
- Department of Chemical Engineering, University of Petroleum and Energy Studies, Dehradun 248007, Uttarakhand, India.
| | - Amit K Thakur
- Department of Chemical Engineering, University of Petroleum and Energy Studies, Dehradun 248007, Uttarakhand, India
| | - Nilanjana Banerjee
- Department of Chemical Engineering, University of Petroleum and Energy Studies, Dehradun 248007, Uttarakhand, India
| | - Pranava Chaudhari
- Department of Chemical Engineering, University of Petroleum and Energy Studies, Dehradun 248007, Uttarakhand, India
| |
Collapse
|
3
|
Supercritical-derived artemisinin microfibers and microparticles for improving anticancer effects. J Supercrit Fluids 2021. [DOI: 10.1016/j.supflu.2021.105276] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
4
|
Alekseev ES, Alentiev AY, Belova AS, Bogdan VI, Bogdan TV, Bystrova AV, Gafarova ER, Golubeva EN, Grebenik EA, Gromov OI, Davankov VA, Zlotin SG, Kiselev MG, Koklin AE, Kononevich YN, Lazhko AE, Lunin VV, Lyubimov SE, Martyanov ON, Mishanin II, Muzafarov AM, Nesterov NS, Nikolaev AY, Oparin RD, Parenago OO, Parenago OP, Pokusaeva YA, Ronova IA, Solovieva AB, Temnikov MN, Timashev PS, Turova OV, Filatova EV, Philippov AA, Chibiryaev AM, Shalygin AS. Supercritical fluids in chemistry. RUSSIAN CHEMICAL REVIEWS 2020. [DOI: 10.1070/rcr4932] [Citation(s) in RCA: 30] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
5
|
Janich C, Friedmann A, Martins de Souza e Silva J, Santos de Oliveira C, de Souza LE, Rujescu D, Hildebrandt C, Beck-Broichsitter M, Schmelzer CEH, Mäder K. Risperidone-Loaded PLGA-Lipid Particles with Improved Release Kinetics: Manufacturing and Detailed Characterization by Electron Microscopy and Nano-CT. Pharmaceutics 2019; 11:E665. [PMID: 31835353 PMCID: PMC6956012 DOI: 10.3390/pharmaceutics11120665] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2019] [Revised: 11/24/2019] [Accepted: 12/02/2019] [Indexed: 12/28/2022] Open
Abstract
For parenteral controlled drug release, the desired zero order release profile with no lag time is often difficult to achieve. To overcome the undesired lag time of the current commercial risperidone controlled release formulation, we developed PLGA-lipid microcapsules (MCs) and PLGA-lipid microgels (MGs). The lipid phase was composed of middle chain triglycerides (MCT) or isopropylmyristate (IPM). Hydroxystearic acid was used as an oleogelator. The three-dimensional inner structure of Risperidone-loaded MCs and MGs was assessed by using the invasive method of electron microscopy with focused ion beam cutting (FIB-SEM) and the noninvasive method of high-resolution nanoscale X-ray computed tomography (nano-CT). FIB-SEM and nano-CT measurements revealed the presence of highly dispersed spherical structures around two micrometres in size. Drug release kinetics did strongly depend on the used lipid phase and the presence or absence of hydroxystearic acid. We achieved a nearly zero order release without a lag time over 60 days with the MC-MCT formulation. In conclusion, the developed lipid-PLGA microparticles are attractive alternatives to pure PLGA-based particles. The advantages include improved release profiles, which can be easily tuned by the lipid composition.
Collapse
Affiliation(s)
- Christopher Janich
- Institute of Pharmacy, Faculty of Biosciences, Martin Luther University Halle-Wittenberg, 06120 Halle (Saale), Germany; (C.J.); (L.E.d.S.)
| | - Andrea Friedmann
- Department of Biological and Macromolecular Materials, Fraunhofer Institute for Microstructure of Materials and Systems IMWS, 06120 Halle (Saale), Germany; (A.F.); (C.E.H.S.)
| | | | | | - Ligia E. de Souza
- Institute of Pharmacy, Faculty of Biosciences, Martin Luther University Halle-Wittenberg, 06120 Halle (Saale), Germany; (C.J.); (L.E.d.S.)
| | - Dan Rujescu
- Department of Psychiatry, Psychotherapy and Psychosomatics, Martin Luther University Halle-Wittenberg, 06120 Halle (Saale), Germany;
| | - Christian Hildebrandt
- MilliporeSigma a Business of Merck KGaA, 64293 Darmstadt, Germany; (C.H.); (M.B.-B.)
| | | | - Christian E. H. Schmelzer
- Department of Biological and Macromolecular Materials, Fraunhofer Institute for Microstructure of Materials and Systems IMWS, 06120 Halle (Saale), Germany; (A.F.); (C.E.H.S.)
| | - Karsten Mäder
- Institute of Pharmacy, Faculty of Biosciences, Martin Luther University Halle-Wittenberg, 06120 Halle (Saale), Germany; (C.J.); (L.E.d.S.)
| |
Collapse
|